Woods Eugene A., an insider at Johnson & Johnson (JNJ), recently purchased 4,841 shares of the company’s stock at a price of $178.07 per share, totaling approximately $862,000. This transaction took place on September 8, 2025.
With this purchase, Woods now holds 4,841 shares of Johnson & Johnson, a company well-known for its extensive portfolio in the healthcare industry. Headquartered in New Brunswick, New Jersey, Johnson & Johnson engages in research, development, manufacture, and sale of various healthcare products. The company operates through two main segments: Innovative Medicine and MedTech, focusing on therapeutic areas such as immunology, oncology, and cardiovascular health.
As of November 20, 2025, Johnson & Johnson boasts a market capitalization of $486.4 billion, a P/E ratio of 19.37, and an EPS of 10.36. The company is also noted for its robust dividend yield of 256.8%. Looking ahead, analysts anticipate earnings of $2.93 per share on revenue of $25.1 billion for the upcoming earnings report on July 14, 2026.
Insider transactions, such as this purchase, can be seen as a positive indicator, reflecting executives' confidence in their company's future. However, it is important for investors to consider these activities within a broader context, examining patterns across multiple insiders and time periods rather than isolated transactions.